Literature DB >> 20704168

Pulmonary arterial hypertension: an update on diagnosis and treatment.

Richard Stringham1, Nipa R Shah.   

Abstract

Pulmonary arterial hypertension is defined as a mean pulmonary arterial pressure greater than 25 mm Hg at rest or 30 mm Hg during physical activity. Pulmonary arterial hypertension is classified into subgroups, including idiopathic, heritable, and pulmonary arterial hypertension associated with other conditions. A detailed history, thorough physical examination, and most importantly, a high index of suspicion are essential to diagnosis. Evaluation includes echocardiography and exclusion of other causes of symptoms. Targeted laboratory testing can help identify the subgroup of pulmonary arterial hypertension. Right heart catheterization is required to confirm the diagnosis. Standard treatment options include oral anticoagulation, diuretics, oxygen supplementation, and for a small percentage of patients, calcium channel blockers. Newer treatments include prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Combination therapy has been shown to improve pulmonary arterial pressure, but more research is needed. Interventional procedures for patients with pulmonary arterial hypertension include balloon atrial septostomy and lung transplantation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20704168

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  6 in total

1.  Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension.

Authors:  Michele Correale; Deodata Montrone; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Clin Res Cardiol       Date:  2012-03-02       Impact factor: 5.460

2.  Patient-specific computational modeling of blood flow in the pulmonary arterial circulation.

Authors:  Vitaly O Kheyfets; Lourdes Rios; Triston Smith; Theodore Schroeder; Jeffrey Mueller; Srinivas Murali; David Lasorda; Anthony Zikos; Jennifer Spotti; John J Reilly; Ender A Finol
Journal:  Comput Methods Programs Biomed       Date:  2015-04-28       Impact factor: 5.428

Review 3.  Pulmonary hypertension: use of oral drugs in patients with renal insufficiency.

Authors:  Sarah Zimner-Rapuch; Sabine Amet; Nicolas Janus; Gilbert Deray; Vincent Launay-Vacher
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

4.  Unilateral pulmonary artery pre-operative occlusion test: technical feasibility and safety prior to pneumonectomy or pleuropneumonectomy for malignancy.

Authors:  Masashi Shimohira; Takuya Hashizume; Kengo Ohta; Kazushi Suzuki; Motoo Nakagawa; Yoshiyuki Ozawa; Katsuhiro Okuda; Satoru Moriyama; Ryoichi Nakanishi; Yuta Shibamoto
Journal:  Br J Radiol       Date:  2017-10-27       Impact factor: 3.039

5.  Simvastatin has beneficial effect on pulmonary artery hypertension by inhibiting NF-κB expression.

Authors:  Zhong-Qiang Liu; Bing Liu; Li Yu; Xiao-Qing Wang; Juan Wang; Han-Min Liu
Journal:  Mol Cell Biochem       Date:  2011-04-05       Impact factor: 3.396

6.  Pulmonary arterial hypertension associated with neurofibromatosis type 1.

Authors:  Miguel F Carrascosa; Isabel Celemín Larroque; Juan-Luis García Rivero; José-Antonio Saiz-Quevedo García; Marta Cano Hoz; Miguel Ares Ares; Xabier Arrastio López; José-Ramón Salcines Caviedes
Journal:  BMJ Case Rep       Date:  2010-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.